OPKO Health and HealthCare Royalty enter $250M note purchase agreement

OPKO Health ( NASDAQ: OPK ) entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA. The $250 million note issued under the Note Purchase Agreement bears interest at the 3-month Secured Overnight Financing Rate subject to a 4.0% per annum floor, plus 7.

5% per annum. The note has a final maturity date of July 2044 with the first four years requiring interest-only payments. Source: Press Release .

More on OPKO Health OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript OPKO down 5% as quarterly results miss on both lines Seeking Alpha’s Quant Rating on OPKO Health Historical earnings data for OPKO Health Financial information for OPKO Health.